Nishant Poddar, MD
Medical Oncology · Ballwin, MONPI 1124387675
Payments from drug & device makers
Across 60 payments — averaging $85.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$3K
- EMD Serono, Inc.$418
- Myriad Genetic Laboratories, Inc.$288
- Astellas Pharma US Inc$200
- AstraZeneca$157
- Incyte Corporation$135
- plus $766 from 20 others
What the payments were for
- Speaking & faculty fees$3,09865%
- Food & beverage$1,26227%
- Education$3808%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 2 | $3,194 |
| EMD Serono, Inc. | 6 | $418 |
| Myriad Genetic Laboratories, Inc. | 2 | $288 |
| Astellas Pharma US Inc | 2 | $200 |
| AstraZeneca | 8 | $157 |
| Incyte Corporation | 4 | $135 |
| Seagen Inc. | 4 | $134 |
| Amgen | 3 | $80 |
| Novartis | 4 | $63 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Gilead | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Lilly USA, LLC | 2 | $47 |
| AbbVie(2 entities) | 2 | $39 |
| Tersera Therapeutics LLC | 1 | $32 |
| Merck | 2 | $28 |
| Grifols USA, LLC | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Morphosys, US Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Advanced Accelerator Applications | 1 | $13 |
| Coherus Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATULINE DEPOT$3,098
- myRisk$265
How this compares
$5,158 in reported general payments places this provider in the 30th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 15 | $1,954 |
| Anastrozole | 20 | $541 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ballwin
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Timothy PluardKansas City$14.7M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.